Emergent Medical Partners, established in 2006, is a California-based venture capital firm specializing in early-stage investments in the life sciences and medical device sectors across the United States. Headquartered in Portola Valley, the firm manages funds from its Mountain View office, targeting innovative healthcare companies for strategic growth.
Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.
Fractyl Health
Series F in 2022
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Standard Bariatrics
Series B in 2021
Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.
Arterys
Series C in 2020
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
EBR Systems
Venture Round in 2019
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Standard Bariatrics
Series A in 2018
Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.
Fractyl Health
Series D in 2017
Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.
Arterys
Series B in 2017
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
Shape Memory Medical
Series B in 2017
Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.
ReThink Medical
Series A in 2017
ReThink Medical, Inc. is a medical device and digital health company based in San Francisco, California, specializing in the development of a wrist-worn monitoring device. Founded in 2010 and now a subsidiary of Terumo Corporation, ReThink Medical focuses on predicting and preventing heart failure hospitalizations through continuous physiological monitoring and advanced machine learning algorithms. Its flagship product, CorBand™, is designed to detect and notify users of worsening heart conditions weeks in advance, even before noticeable symptoms emerge. This proactive approach emphasizes compliance, simplicity, and accuracy, aiming to improve quality of life for patients while significantly reducing healthcare costs. The device monitors key indicators such as heartbeat rate and fluid status, enabling timely intervention and management of heart-related disorders.
Relievant Medsystems
Series D in 2016
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.
Chrono Therapeutics
Series B in 2016
Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.
Arterys
Series A in 2016
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
Arterys
Series A in 2015
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
Twelve
Series C in 2015
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.
EBR Systems
Venture Round in 2015
EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.
Focal Therapeutics
Venture Round in 2014
Focal Therapeutics, Inc. is a medical device company based in Aliso Viejo, California, established in 2007. The company specializes in the development and manufacture of the BioZorb tissue marker, an innovative implantable device designed to provide three-dimensional radiographic marking of surgical sites, particularly in breast surgery. BioZorb is placed by surgeons at the time of tissue removal, helping to accurately delineate the excision site for subsequent medical procedures, treatment planning, and follow-up imaging. The device's unique design assists surgeons, radiation oncologists, and other clinicians in identifying surgical sites, which is essential for effective patient care. Focal Therapeutics operates as a subsidiary of Hologic, Inc., and its leadership team possesses extensive experience in the medical device sector, particularly in breast cancer care.
SinuSys
Series D in 2013
SinuSys Corporation is a medical device company focused on developing innovative therapies to enhance patient health, particularly in the area of sinus health. The company has created a straightforward, two-step interventional procedure aimed at alleviating symptoms of sinusitis. Utilizing osmotic technology, SinuSys designs dilation devices specifically for treating frontal and sphenoid sinus issues, as well as other ear, nose, and throat problems. This approach enables patients to access effective and reliable treatments for their sinus-related conditions.
Nanostim
Venture Round in 2013
NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.
Nanostim
Venture Round in 2012
NanoStim is an early-stage medical device company focused on developing a miniaturized, leadless cardiac pacemaker aimed at reducing complications associated with traditional pacemakers, which affect over 100,000 individuals annually. The company has assembled a highly skilled team of medical device engineers to advance this innovative technology, which is designed for direct implantation in a cardiac chamber without the need for leads. By offering a leadless pacing solution, NanoStim seeks to improve patient outcomes and enhance the safety and effectiveness of cardiac interventions.
Biomimedica
Series B in 2012
Biomimedica is a medical device company based in South San Francisco, California, founded in 2007. The company specializes in developing innovative synthetic cartilage technology aimed at joint repair. Its proprietary material is designed to restore the surface of damaged joints, providing a solution for individuals suffering from joint-related issues. Through its advanced approaches, Biomimedica is contributing to the evolution of joint repair methods in the medical field.
Relievant Medsystems
Series D in 2012
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.
CytoPherx
Series C in 2012
CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system.
Crux Biomedical
Series C in 2011
Crux Biomedical, Inc., established in August 2004 by physicians Tom Fogarty and Frank Arko, focuses on developing innovative medical devices to address the limitations of existing vena cava filters. The company's primary product, the Crux VCF System, serves as a preventive device for pulmonary embolisms, effectively stopping blood clots from reaching the lungs. This system is particularly beneficial for patients at risk of pulmonary embolism who are unable to tolerate blood thinners, providing a vital method for preventing potentially life-threatening clots.
OncoHealth
Series A in 2011
OncoHealth is a company that specializes in creating screening devices aimed at the detection and diagnosis of cancer. The primary focus of its devices is the development of protein bio-markers, which are essential for the screening and diagnostic processes related to cervical cancer and other cancers associated with human papillomavirus (HPV). By advancing these technologies, OncoHealth enables medical professionals to effectively monitor, diagnose, and treat cancer, thereby contributing to improved patient outcomes in oncology.
Cianna Medical
Series B in 2011
Cianna Medical, Inc. is a women’s health company focused on innovative solutions for the treatment of early-stage breast cancer. Based in Aliso Viejo, California, the company develops advanced medical technologies designed to enhance breast conservation therapy. Its primary products include SAVI SCOUT, a wire-free radar localization system that assists in accurately locating breast tumors, and SAVI Brachy, which delivers targeted radiation therapy to minimize damage to surrounding healthy tissue. Additionally, Cianna Medical provides BrachyBytes, an e-newsletter that shares insights and expert interviews on breast brachytherapy. Incorporated in 2007, the company aims to expand access to effective treatment options for women diagnosed with breast cancer, improving their chances for successful outcomes. As of November 2018, Cianna Medical operates as a subsidiary of Merit Medical Systems, Inc.
Sonoma Orthopedic Products
Series D in 2011
Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.
Incline Therapeutics
Series A in 2010
Incline Therapeutics is a privately-held specialty pharmaceutical company that focuses on the development of IONSYS, a fentanyl iontophoretic transdermal system designed for adult inpatients needing opioid pain relief following surgery. The company is dedicated to creating a compact, disposable, needleless Patient-Controlled Analgesia system that facilitates the short-term management of postoperative pain. Incline Therapeutics is backed by prominent life science venture capital firms and is led by a management team with extensive experience in the pharmaceutical and medical device sectors.
Reverse Medical
Series B in 2010
Reverse Medical is a commercial-stage medical device company dedicated to developing innovative solutions for revascularizing patients suffering from acute ischemic strokes. The company specializes in creating embolic protection systems aimed at treating neurovascular disorders, with a strong emphasis on endovascular management of acute stroke conditions. Through its advanced medical technologies, Reverse Medical seeks to improve patient outcomes and enhance the overall standard of care in the treatment of stroke.
Intuity Medical
Series D in 2010
Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.
Cyberheart
Debt Financing in 2009
CyberHeart, Inc. is a clinical development-stage company based in Mountain View, California, focused on creating a non-invasive robotic ablation treatment for cardiac arrhythmias, including conditions like atrial fibrillation and ventricular tachycardia. The company's flagship product, the CyberHeart System, utilizes advanced technology to dynamically detect, track, and compensate for the movement of both the heart and the patient, ensuring precise radiation delivery. This system is designed for use by healthcare professionals such as radiation oncologists, medical physicists, electrophysiologists, and cardiac surgeons. Founded in 2003 and operating as a subsidiary of Varian Medical Systems as of April 2019, CyberHeart has been conducting pre-clinical studies to validate the feasibility of its innovative technology. The company has also secured venture capital financing to support its development efforts.
Relievant Medsystems
Series C in 2009
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.
Ardian
Series C in 2009
Ardian, established in 1996, is a France-based asset manager offering global investment management services. It primarily focuses on fund of funds (55.21%), followed by direct funds (19.79%), infrastructure (16.67%), and private debt (7.29%), with a minor allocation to real estate (1.04%). Ardian invests across various sectors, including food value chain, healthcare, technology, and industrials, with a presence in Europe and North America.
Biomimedica
Series A in 2008
Biomimedica is a medical device company based in South San Francisco, California, founded in 2007. The company specializes in developing innovative synthetic cartilage technology aimed at joint repair. Its proprietary material is designed to restore the surface of damaged joints, providing a solution for individuals suffering from joint-related issues. Through its advanced approaches, Biomimedica is contributing to the evolution of joint repair methods in the medical field.
Cyberheart
Series A in 2008
CyberHeart, Inc. is a clinical development-stage company based in Mountain View, California, focused on creating a non-invasive robotic ablation treatment for cardiac arrhythmias, including conditions like atrial fibrillation and ventricular tachycardia. The company's flagship product, the CyberHeart System, utilizes advanced technology to dynamically detect, track, and compensate for the movement of both the heart and the patient, ensuring precise radiation delivery. This system is designed for use by healthcare professionals such as radiation oncologists, medical physicists, electrophysiologists, and cardiac surgeons. Founded in 2003 and operating as a subsidiary of Varian Medical Systems as of April 2019, CyberHeart has been conducting pre-clinical studies to validate the feasibility of its innovative technology. The company has also secured venture capital financing to support its development efforts.
HeartFlow
Seed Round in 2008
HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.